Skip to main content

Table 1 Therapy types included in the survey, each on a separate page. Therapies A–R were explicitly asked for, while S–U and V–X were included as complement

From: Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Annotation Therapy type
A 131I-NaI for benign thyroid diseases
B 131I-NaI for thyroid remnant ablation of adults
C 131I-NaI for thyroid remnant ablation of children and young adults
D 131I-NaI for thyroid cancer therapy for adults
E 131I-NaI for thyroid cancer therapy for children and young adults
F 131I-mIBG for neuroblastoma
G 131I-mIBG for adult neuroendocrine tumors
H 177Lu-somatostatin analogues for neuroendocrine tumors
I 90Y-somatostatin analogues for neuroendocrine tumors
J 177Lu-PSMA therapy of castration resistant prostate cancer
K 90Y resin microspheres (SIR-Spheres®) for intra-arterial treatments in the liver
L 90Y glass microspheres (TheraSphere®) for intra-arterial treatments in the liver
M Radiation synovectomy using 90Y-, 186Re-, or 169Er-colloids
N 153Sm-EDTMP (Quadramet®) for bone metastases
O 89SrCl2 (Metastron®) for bone metastases
P 223RaCl2 (Xofigo®) for bone metastases
Q 32P sodium-phosphate (Na3 32PO4) for myeloproliferative disease
R 90Y-ibritumomab-tiuxetan (Zevalin®) for B-cell lymphoma
S–U Therapy using alpha emitting radionuclides other than 223Ra
V–X Therapy using other radiopharmaceutical